HOME >> BIOLOGY >> NEWS
Drunken worms reveal a genetic basis of alcohol response

Since one of the basic risk factors for alcoholism is a tolerance to alcohol, researchers have long sought to understand the genetic differences among people that affect their sensitivity to alcohol. So far, scientists have met with little success.

However, by exposing populations of the roundworm C. elegans to alcohol and pinpointing subtle genetic differences among strains that respond differently, researchers have identified one gene that affects alcohol sensitivity.

In an article in the June 10, 2004, issue of Neuron, Andrew Davies and his colleagues describe their findings that subtle differences between worm strains in the gene for a brain protein called NPR-1 explains differences in the worms' alcohol sensitivity.

The researchers chose the worm as their subject because there is evidence that alcohol has effects on worm behavior. Although the mechanisms that mediate alcohol response in humans or other animals are not well understood, most human neuronal proteins have worm versions and it seems likely that at least some of the mechanisms are shared. Additionally, the worm has been the subject of massive genetic study by scientists, and genetically distinct strains are available from around the world.

In their experiments, Davies and his colleagues exposed two wild strains of worms -- one from England and one from Hawaii to alcohol and compared how they showed "acute tolerance" when first exposed to ethanol. The researchers used alcohol concentrations comparable to those that cause intoxication in humans.

The researchers measured the worms' responses by how much slower their movement became after exposure. The Hawaiian worms showed a more dramatic recovery from initial intoxication than did the English worms.

Genetic analyses of the two strains led to a subtle difference between the strains in the gene for NPR-1. The genetic difference, their experiments showed, caused p
'"/>

Contact: Heidi Hardman
hhardman@cell.com
617-397-2879
Cell Press
9-Jun-2004


Page: 1 2

Related biology news :

1. Drunken Fruit Flies Reveal Molecular Pathway Regulating Sensitivity To Alcohol
2. Convulsions in worms mimic epileptic seizures
3. Heartless worms hold clues to cardiac arrhythmias, sudden death
4. Whale carcass yields bone-devouring worms
5. Oxygen sensing in worms may hold key to healthy blood pressure in humans
6. Researchers discover how worms noses sense oxygen
7. Study in worms shows how genes linked to complexity in animals
8. Two worms are better than one
9. Cows resistance to worms is genetically determined
10. Alien earthworms changing ecology of Northeast forests
11. Amorous worms reveal effects of Chernobyl

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Drunken worms reveal genetic basis alcohol response

(Date:4/13/2015)... CHICAGO , April 13, 2015  higi, a ... with ways to more fully engage with their communities ... its industry-leading, privacy protected and secure API.  ... API enables the most accessible, affordable, and convenient vehicle ... The API will ...
(Date:4/9/2015)... Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the third quarter of ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-438-5524 (conference ...
(Date:4/6/2015)... Conn. , Apr. 6, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/143028 for ... COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces a ... payments. This patent surrounds the use of miniature ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
(Date:4/17/2015)... Houston, TX (PRWEB) April 17, 2015 ... genomics and proteomics technologies, announced today that it ... sequencing system, an innovative multiplex PCR based targeted ... ultra-high resolution sequence analysis, that enables accurate detection ... pending Relay-PCR™ and Omega-Primer™ technologies. The company will ...
(Date:4/16/2015)... 16, 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) ... quarter results on Thursday, April 30, 2015 at 4:00 ... will host a conference call at 4:30 PM Eastern ... company’s outlook for the future. , The conference call ... the homepage and in the Investor Relations section of ...
(Date:4/16/2015)... According to the 2014 Liberty ... source was ranked first among the leading causes ... lifting, pushing, pulling, holding, carrying, or throwing and ... David Round Company takes statistics like this very ... to develop and design equipment that prevents these ...
(Date:4/16/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... venture with G-treeBNT (ReGenTree LLC) has retained Ora, ... for the orphan disorder, neurotrophic keratopathy (NK), and ... syndrome (DES) in the U.S.  Both trials will ... year.  Each of these eye disorders was being ...
Breaking Biology Technology:LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 2LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 3Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5
Cached News: